Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2639)	10/15/2009 9:17:55 AM
From: Jibacoa	Respond to of 3722

ACOR is up 52.09% on premarket trading. It announced today that an FDA committee voted 12 to 1 that in favor of Fampridine-SR 10 mg BID based on data that demonstrated evidence of effectiveness treating patients with MS, helping to improve walking and also voted 10 to 2 with 1 abstention, that it is clinically meaningful and can be safe for use.<g> The stock is closing its Oct 9 DG trading at $25.13 in premarket bigcharts.marketwatch.com The ACTAY is $27.63 The stock needs to close above the $27 level in order to get off from its longer term DT coming from the Aug 2008 H at $35.65 bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2639)	4/28/2010 12:20:41 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

SURG opened with a good UG, was up 72.43% and is still up 37.30% at present on volume of >1.1M about 16.8x its ADV.<g> bigcharts.marketwatch.com It said that it has entered into a $32M agreement with ACL for the right to sell certain SURG's patented products worldwide and they have ended all previous litigation matters between them.<g> The stock traded earlier today above my previous target of $3. The earnings on the 2ndQ were 100% better on slightly lower revenue. I will have to readjust my target, but will better wait to see how much of today's UG will be closed.<g> The stock seems to have a good amount of resistance at the $4 level bigcharts.marketwatch.com Bernard